Truist upgraded Globus Medical (GMED) to Buy from Hold with a price target of $93, up from $65. The firm has greater confidence in the company’s mid- to high-single-digit revenue growth outlook with low- to mid-teens earnings growth. Nevro accretion is getting pulled forward nearly one year ahead of expectations while Globus is seeing accelerating trends in the core spine business, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: